Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LA-002
- Development stage
- Unknown
- Lead developer
- Allero Therapeutics
01
Overview
LA-002 is an investigational therapeutic being developed by Allero Therapeutics for the treatment of food hypersensitivity. The drug is in the discovery phase and is part of Allero Therapeutics' proprietary Specific Immunotherapy platform, which aims to induce immune tolerance to specific allergens. The precise mechanism of action, molecular target, and modality have not been publicly disclosed as of June 2025[1][2].
- Other names
- LA 002LA002LA-002
Beyond the preview
Go deeper on LA-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LA-002.